Carcinoembryonic Antigen as a Monitor in Breast Cancer
Article first published online: 9 MAY 2013
American Journal of Reproductive Immunology
Volume 1, Issue 5, pages 269–271, October 1981
How to Cite
CILLARI, E., BELLAVIA, A., ROMANO, G. C., DI GESU, G., PALMERI, S., NORATO, A., SALERNO, A. and VOTI, P. L. (1981), Carcinoembryonic Antigen as a Monitor in Breast Cancer. American Journal of Reproductive Immunology, 1: 269–271. doi: 10.1111/j.1600-0897.1981.tb00053.x
- Issue published online: 9 MAY 2013
- Article first published online: 9 MAY 2013
- Accepted April 22, 1981
- Carcinoembryonic antigen;
- breast cancer
ABSTRACT: Carcinoembryonic antigen (CEA) levels were serially determined in 125 patients with breast cancer in order to study the diagnostic and prognostic use of serum CEA levels before and/or after surgery and during treatment with hormonal and chemotherapy. Serum CEA levels were elevated in 15.5% of nonmetastatic patients. Carcinoembryonic antigen increased according to stage (TNM classification); and a direct relationship between positive CEA levels and subsequent recurrence was found. After a three-year postoperative interval a 50% survival rate was exhibited in CEA-positive patients vs an 88% survival rate in those patients found to be CEA negative.
There is a definite correlation between the trend of serial CEA values and the response to therapy and the development of metastases despite the fact that metastases occurred in CEA-negative patients.
Therefore CEA assay is a useful and simple adjuvant test of monitoring metastatic and nonmetastatic breast cancer.